# US 2025/0082586 A1 · Compositions for treating inflammatory, neurologic and/or vascular conditions and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082586 A1
- Document ID: US20250082586A1
- Status: Published application
- Kind: A1
- Application number: 18/561,386
- Filed: 2022-05-18
- Published: 2025-03-13
- Earliest claimed: 2021-05-21
- Inventors: Brian Stuart Murphy
- Web page: https://patentgrep.com/patent/US20250082586A1

## CPC

- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/4858: {Organic compounds}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described are pharmaceutical compositions for treating an inflammatory condition, a neurologic condition and/or a vascular condition, the composition including i) a cannabinoid and ii) a modulator compound that acts as one or more of an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator. Further described are methods of treating inflammatory, neurologic and/or vascular conditions.

## Claims

### Claim 1

A method of treating post-infectious encephalopathy comprising administering to a subject i) a cannabinoid and ii) a modulator compound that acts as one or more of an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator.

### Claim 2 (depends on 1)

The method of claim 1, wherein the NMDA receptor modulator is an agonist, an antagonist, or a mixed agonist-antagonist at one or more of the NMDA receptor modulator, the 5-HT3 receptor modulator, the nicotinic acetylcholine receptor modulator, the dopamine D2 receptor modulator, or the sigma-1 receptor modulator.

### Claim 3 (depends on 1)

The method of claim 1, wherein the modulator compound is an NMDA receptor antagonist.

### Claim 4 (depends on 1)

The method of claim 1, wherein the modulator compound is glutamatergic NMDA receptor antagonist.

### Claim 5 (depends on 1)

The method of claim 1, wherein the modulator compound is 5-HT3 receptor antagonist.

### Claim 6 (depends on 1)

The method of claim 1, wherein the modulator compound is a nicotinic acetylcholine receptor antagonist.

### Claim 7 (depends on 1)

The method of claim 1, wherein the modulator compound is a dopamine D2 receptor agonist.

### Claim 8 (depends on 1)

The method of claim 1, wherein the modulator compound is a sigma-1 receptor agonist.

### Claim 9 (depends on 1)

The method of claim 1, wherein the modulator compound is memantine, a prodrug thereof, an analog thereof, a metabolite thereof or a pharmaceutically acceptable salt thereof.

### Claim 10

A method of treating post COVID-19 syndrome comprising administering to a subject i) a cannabinoid and ii) a modulator compound that acts as one or more of an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator;
wherein the NMDA receptor modulator is an agonist, an antagonist, or a mixed agonist-antagonist at one or more of the NMDA receptor modulator, the 5-HT3 receptor modulator, the nicotinic acetylcholine receptor modulator, the dopamine D2 receptor modulator, or the sigma-1 receptor modulator;
wherein the modulator compound is an NMDA receptor antagonist;
wherein the modulator compound is glutamatergic NMDA receptor antagonist;
wherein the modulator compound is 5-HT3 receptor antagonist;
wherein the modulator compound is a nicotinic acetylcholine receptor antagonist;
wherein the modulator compound is a dopamine D2 receptor agonist;
wherein the modulator compound is a sigma-1 receptor agonist;
wherein the modulator compound is memantine, a prodrug thereof, an analog thereof, a metabolite thereof or a pharmaceutically acceptable salt thereof.

### Claim 11

A pharmaceutical composition comprising i) a cannabinoid and ii) a modulator compound that acts as one or more of an NMDA receptor modulator, a 5-HT3 receptor modulator, a nicotinic acetylcholine receptor modulator, a dopamine D2 receptor modulator, or a sigma-1 receptor modulator.

### Claim 12 (depends on 11)

The pharmaceutical composition of claim 11, wherein the NMDA receptor modulator is an agonist, an antagonist, or a mixed agonist-antagonist at one or more of the NMDA receptor modulator, the 5-HT3 receptor modulator, the nicotinic acetylcholine receptor modulator, the dopamine D2 receptor modulator, or the sigma-1 receptor modulator.

### Claim 13 (depends on 11)

The pharmaceutical composition of claim 11, wherein the modulator compound is an NMDA receptor antagonist.

### Claim 14 (depends on 11)

The pharmaceutical composition of claim 11, wherein the modulator compound is 5-HT3 receptor antagonist.

### Claim 15 (depends on 11)

The pharmaceutical composition of claim 11, wherein the modulator compound is a nicotinic acetylcholine receptor antagonist.

### Claim 16 (depends on 11)

The pharmaceutical composition of claim 11, wherein the modulator compound is a dopamine D2 receptor agonist.

### Claim 17 (depends on 11)

The pharmaceutical composition of claim 11, wherein the modulator compound is a sigma-1 receptor agonist.

### Claim 18 (depends on 11)

The pharmaceutical composition of claim 11, wherein the modulator compound is memantine, a prodrug thereof, an analog thereof, a metabolite thereof or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 11)

The pharmaceutical composition of claim 11, wherein the cannabinoid comprises one or more of cannabinol, cannabidiol, cannabigerol, cannabichromene, Δ9-tetrahydrocannabinol, Δ8-tetrahydrocannabinol, 11-hydroxy-tetrahydrocannabinol, 11-hydroxy-Δ9-tetrahydrocannabinol, levonantradol, Δ11-tetrahydrocannabinol, tetrahydrocannabivarin (THCV), dronabinol, amandamide, nabilone, cannabidivarin (CBDV), a cannavinoid-varin compound, a derivative thereof, a prodrug thereof, an analog thereof, a metabolite thereof or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 11)

The pharmaceutical composition of claim 11, wherein the cannabinoid is cannabidiol hemisuccinate or tetrahydrocannabinol-hemisuccinate.
